Adachi Hiroki, Nakayama Kanae, Hayashi Norifumi, Matsui Yuki, Fujimoto Keiji, Yamaya Hideki, Tonami Hisao, Yokoyama Hitoshi
Department of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Ishikawa, Japan.
Department of Radiology, Kanazawa Medical University School of Medicine, Uchinada, Ishikawa, Japan.
PLoS One. 2016 Oct 5;11(10):e0163899. doi: 10.1371/journal.pone.0163899. eCollection 2016.
A few studies have investigated the role of adiponectin fraction for cardiovascular disease (CVD) in RTx recipients.
We studied 57 adult subjects (39 males, 18 females; 10 cadaveric donors) with at least three years of allograft survival (median 251 months). We examined clinical backgrounds such as treated drugs, blood pressure (BP, mmHg), body mass index (BMI), and blood chemistry including cholesterol (total, LDL-C, HDL-C), glucose, glycated hemoglobin (HbA1c), and serum high and low-molecular-weight (HMW/LMW) ADPN fractions with regard to the associations of the visceral and subcutaneous fat areas on CT scan. We also analyzed the associations of CVD and post-transplant diabetes (PTDM) with ADPN fractions and the fat areas.
The visceral fat area was inversely correlated with serum HMW and LMW ADPN levels and HMW ADPN ratio (r = -0.400, p = 0.002 and r = -0.296, p = 0.025 and r = -0.444, p<0.001, respectively). Furthermore, the visceral fat area was positively with the LMW ADPN ratio (r = 0.467, p<0.001), but no significant correlation was noted between the subcutaneous fat area and the ADPN ratio. On multiple regression analysis, eGFR and the visceral fat area were significant reducing factors of HMW ADPN levels, and the alteration of eGFR was identified as an increasing factor of HMW ADPN levels. Patients with CVD had larger visceral fat area (p = 0.004), lower HMW ADPN ratio (p = 0.022) and higher LMW ADPN ratio (p = 0.049). In addition, the higher HMW ADPN ratio and statin treatment were identified as reducing factors of the development of CVD, but the LDL-C level was an aggravating factor. Moreover, the higher LMW ADPN ratio and the visceral fat area were aggravating factors of PTDM.
Even in Japanese renal transplant recipients, visceral fat area and ADPN fractions were significant factors for the development of both CVD and PTDM.
少数研究调查了脂联素组分在肾移植受者心血管疾病(CVD)中的作用。
我们研究了57名成年受试者(39名男性,18名女性;10名尸体供者),其同种异体移植存活至少三年(中位数为251个月)。我们检查了临床背景,如所服用的药物、血压(BP,mmHg)、体重指数(BMI)以及血液生化指标,包括胆固醇(总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇)、血糖、糖化血红蛋白(HbA1c),以及血清高分子量和低分子量(HMW/LMW)脂联素组分,并分析了CT扫描中内脏和皮下脂肪面积之间的关联。我们还分析了CVD和移植后糖尿病(PTDM)与脂联素组分及脂肪面积之间的关联。
内脏脂肪面积与血清HMW和LMW脂联素水平以及HMW脂联素比率呈负相关(r = -0.400,p = 0.002;r = -0.296,p = 0.025;r = -0.444,p<0.001)。此外,内脏脂肪面积与LMW脂联素比率呈正相关(r = 0.467,p<0.001),但皮下脂肪面积与脂联素比率之间未发现显著相关性。在多元回归分析中,估算肾小球滤过率(eGFR)和内脏脂肪面积是HMW脂联素水平的显著降低因素,而eGFR的改变被确定为HMW脂联素水平的增加因素。患有CVD的患者内脏脂肪面积更大(p = 0.004),HMW脂联素比率更低(p = 0.022),LMW脂联素比率更高(p = 0.049)。此外,较高的HMW脂联素比率和他汀类药物治疗被确定为CVD发生的降低因素,但低密度脂蛋白胆固醇水平是加重因素。而且,较高的LMW脂联素比率和内脏脂肪面积是PTDM的加重因素。
即使在日本肾移植受者中,内脏脂肪面积和脂联素组分也是CVD和PTDM发生的重要因素。